Labcorp Provides 2026 Financial Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy LH?
Source: PRnewswire
- 2025 Performance Growth: Labcorp achieved over 7% revenue growth in 2025, with double-digit adjusted EPS growth, reflecting strong performance in its Diagnostics and Central Laboratory businesses, thereby enhancing its competitive position in the market.
- Shareholder Return Plan: The company announced a quarterly cash dividend of $0.72 per share, payable on March 12, 2026, demonstrating its commitment to shareholders, while repurchasing $225 million of common stock in 2025, further boosting EPS.
- 2026 Financial Outlook: Labcorp expects total revenue to reach $13.955 billion in 2026, representing a growth of 4.7% to 6.0% compared to 2025, with adjusted EPS projected between $16.44 and $18.25, reflecting confidence in future growth.
- Cash Flow Performance: The free cash flow for 2025 was $1.206 billion, showing a decrease from 2024, yet still indicating strong capabilities in capital allocation and operational efficiency, supporting future investments and shareholder returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 278.110
Low
270.00
Averages
304.45
High
325.00
Current: 278.110
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Labcorp Q4 Earnings Beat Expectations, 2026 Outlook Positive
- Earnings Highlights: Labcorp's Q4 Non-GAAP EPS of $4.07 exceeded expectations by $0.13, indicating strong profitability, although revenue of $3.52 billion, up 5.7% year-over-year, fell short of market expectations by $40 million.
- Free Cash Flow Trends: The company reported Q4 free cash flow of $490.3 million, a significant drop from $665.1 million year-over-year, while full-year free cash flow reached $1.21 billion, surpassing the $1.10 billion forecast, reflecting effective cash management.
- 2026 Financial Guidance: Labcorp's guidance for 2026 enterprise revenue is set between $14.61 billion and $14.79 billion, with a midpoint growth of 5.4%, exceeding the $14.63 billion consensus, demonstrating confidence in future growth prospects.
- Earnings Per Share Outlook: The adjusted EPS guidance ranges from $17.55 to $18.25, with a midpoint growth of 8.9%, surpassing the market expectation of $17.52, indicating ongoing improvements in profitability and competitive positioning.
See More
Labcorp Provides 2026 Financial Guidance
- 2025 Performance Growth: Labcorp achieved over 7% revenue growth in 2025, with double-digit adjusted EPS growth, reflecting strong performance in its Diagnostics and Central Laboratory businesses, thereby enhancing its competitive position in the market.
- Shareholder Return Plan: The company announced a quarterly cash dividend of $0.72 per share, payable on March 12, 2026, demonstrating its commitment to shareholders, while repurchasing $225 million of common stock in 2025, further boosting EPS.
- 2026 Financial Outlook: Labcorp expects total revenue to reach $13.955 billion in 2026, representing a growth of 4.7% to 6.0% compared to 2025, with adjusted EPS projected between $16.44 and $18.25, reflecting confidence in future growth.
- Cash Flow Performance: The free cash flow for 2025 was $1.206 billion, showing a decrease from 2024, yet still indicating strong capabilities in capital allocation and operational efficiency, supporting future investments and shareholder returns.
See More
Key Companies to Monitor This Week: PCE, Walmart, Palo Alto, Analog Devices, Deere, and Others
- Market Performance: Equities experienced a decline last week, with all three major indexes falling by at least 1.2%.
- Economic Indicators: This downturn occurred despite a better-than-expected jobs report from the Bureau of Labor Statistics and a relatively stable inflation report.
See More
Powell's Tenure Nears End, Market Focuses on His Legacy
- Monetary Policy Balance: As Fed Chair Powell's tenure approaches its end, the market is keenly focused on his performance in balancing maximum employment and stable prices, especially with the upcoming release of the latest meeting minutes, marking one of his final meetings in office.
- Interest Rate Challenges: During Powell's leadership, the Fed has navigated emergency interventions and an aggressive rate-hiking cycle, with the benchmark rate rising from near zero to over 5%; despite initially viewing inflation as 'transitory,' achieving a 'soft landing' for the economy will be a key part of his legacy.
- Market Reaction Expectations: Investors are optimistic about the upcoming personal consumption expenditure data, although the cooler-than-expected CPI could impact the Fed's interest rate outlook, with markets currently pricing in only two quarter-point cuts for the year.
- Industry Dynamics Observation: As concerns over AI disruption grow, stocks in software, finance, and real estate have seen declines, prompting investors to search for the next potentially affected sectors, with Walmart and Deere's upcoming earnings reports likely to be focal points for market attention.
See More
Labcorp to Announce Q4 Earnings on February 17
- Earnings Announcement Date: Labcorp Holdings (LH) is set to announce its Q4 earnings on February 17 before market open, with a consensus EPS estimate of $3.94, reflecting a 14.2% year-over-year growth, indicating sustained profitability potential for the company.
- Revenue Expectations: The anticipated revenue for Q4 is $3.56 billion, representing a 6.9% year-over-year increase, which underscores the stable demand in the medical testing sector and potential market share gains, likely boosting investor confidence moving forward.
- Historical Performance Review: Over the past two years, Labcorp has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing the company's reliability in financial performance and enhancing market confidence in its future results.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 3 downward revisions, while revenue estimates have also experienced 2 upward and 3 downward revisions, indicating market uncertainty regarding the company's future performance, which investors should monitor closely ahead of the earnings release.
See More
Labcorp Launches First Blood Test for Alzheimer's Disease
- First Blood Test: Labcorp's Elecsys® pTau-181 test is the first blood test cleared by the FDA for the initial assessment of Alzheimer's disease, representing a significant breakthrough in primary care that enables earlier identification of patient conditions.
- Expanded Testing Access: This test allows primary care clinicians to quickly rule out Alzheimer's disease when patients present cognitive symptoms, thereby enhancing patient care efficiency and reducing reliance on specialists, optimizing healthcare resource allocation.
- Market Demand Response: With approximately 7.2 million Americans living with Alzheimer's disease, Labcorp's launch of this test addresses the urgent need for early diagnosis and assessment, further solidifying its leadership position in the blood testing market for Alzheimer's disease.
- Research Support: Labcorp has supported over 90 Alzheimer's disease research protocols in the past five years, showcasing its deep expertise in biomarker development aimed at advancing early diagnosis and treatment progress for Alzheimer's disease.
See More
Labcorp Q4 Earnings Beat Expectations, 2026 Outlook Positive
- Earnings Highlights: Labcorp's Q4 Non-GAAP EPS of $4.07 exceeded expectations by $0.13, indicating strong profitability, although revenue of $3.52 billion, up 5.7% year-over-year, fell short of market expectations by $40 million.
- Free Cash Flow Trends: The company reported Q4 free cash flow of $490.3 million, a significant drop from $665.1 million year-over-year, while full-year free cash flow reached $1.21 billion, surpassing the $1.10 billion forecast, reflecting effective cash management.
- 2026 Financial Guidance: Labcorp's guidance for 2026 enterprise revenue is set between $14.61 billion and $14.79 billion, with a midpoint growth of 5.4%, exceeding the $14.63 billion consensus, demonstrating confidence in future growth prospects.
- Earnings Per Share Outlook: The adjusted EPS guidance ranges from $17.55 to $18.25, with a midpoint growth of 8.9%, surpassing the market expectation of $17.52, indicating ongoing improvements in profitability and competitive positioning.
See More
Labcorp Provides 2026 Financial Guidance
- 2025 Performance Growth: Labcorp achieved over 7% revenue growth in 2025, with double-digit adjusted EPS growth, reflecting strong performance in its Diagnostics and Central Laboratory businesses, thereby enhancing its competitive position in the market.
- Shareholder Return Plan: The company announced a quarterly cash dividend of $0.72 per share, payable on March 12, 2026, demonstrating its commitment to shareholders, while repurchasing $225 million of common stock in 2025, further boosting EPS.
- 2026 Financial Outlook: Labcorp expects total revenue to reach $13.955 billion in 2026, representing a growth of 4.7% to 6.0% compared to 2025, with adjusted EPS projected between $16.44 and $18.25, reflecting confidence in future growth.
- Cash Flow Performance: The free cash flow for 2025 was $1.206 billion, showing a decrease from 2024, yet still indicating strong capabilities in capital allocation and operational efficiency, supporting future investments and shareholder returns.
See More
Key Companies to Monitor This Week: PCE, Walmart, Palo Alto, Analog Devices, Deere, and Others
- Market Performance: Equities experienced a decline last week, with all three major indexes falling by at least 1.2%.
- Economic Indicators: This downturn occurred despite a better-than-expected jobs report from the Bureau of Labor Statistics and a relatively stable inflation report.
See More
Powell's Tenure Nears End, Market Focuses on His Legacy
- Monetary Policy Balance: As Fed Chair Powell's tenure approaches its end, the market is keenly focused on his performance in balancing maximum employment and stable prices, especially with the upcoming release of the latest meeting minutes, marking one of his final meetings in office.
- Interest Rate Challenges: During Powell's leadership, the Fed has navigated emergency interventions and an aggressive rate-hiking cycle, with the benchmark rate rising from near zero to over 5%; despite initially viewing inflation as 'transitory,' achieving a 'soft landing' for the economy will be a key part of his legacy.
- Market Reaction Expectations: Investors are optimistic about the upcoming personal consumption expenditure data, although the cooler-than-expected CPI could impact the Fed's interest rate outlook, with markets currently pricing in only two quarter-point cuts for the year.
- Industry Dynamics Observation: As concerns over AI disruption grow, stocks in software, finance, and real estate have seen declines, prompting investors to search for the next potentially affected sectors, with Walmart and Deere's upcoming earnings reports likely to be focal points for market attention.
See More
Labcorp to Announce Q4 Earnings on February 17
- Earnings Announcement Date: Labcorp Holdings (LH) is set to announce its Q4 earnings on February 17 before market open, with a consensus EPS estimate of $3.94, reflecting a 14.2% year-over-year growth, indicating sustained profitability potential for the company.
- Revenue Expectations: The anticipated revenue for Q4 is $3.56 billion, representing a 6.9% year-over-year increase, which underscores the stable demand in the medical testing sector and potential market share gains, likely boosting investor confidence moving forward.
- Historical Performance Review: Over the past two years, Labcorp has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing the company's reliability in financial performance and enhancing market confidence in its future results.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 3 downward revisions, while revenue estimates have also experienced 2 upward and 3 downward revisions, indicating market uncertainty regarding the company's future performance, which investors should monitor closely ahead of the earnings release.
See More
Labcorp Launches First Blood Test for Alzheimer's Disease
- First Blood Test: Labcorp's Elecsys® pTau-181 test is the first blood test cleared by the FDA for the initial assessment of Alzheimer's disease, representing a significant breakthrough in primary care that enables earlier identification of patient conditions.
- Expanded Testing Access: This test allows primary care clinicians to quickly rule out Alzheimer's disease when patients present cognitive symptoms, thereby enhancing patient care efficiency and reducing reliance on specialists, optimizing healthcare resource allocation.
- Market Demand Response: With approximately 7.2 million Americans living with Alzheimer's disease, Labcorp's launch of this test addresses the urgent need for early diagnosis and assessment, further solidifying its leadership position in the blood testing market for Alzheimer's disease.
- Research Support: Labcorp has supported over 90 Alzheimer's disease research protocols in the past five years, showcasing its deep expertise in biomarker development aimed at advancing early diagnosis and treatment progress for Alzheimer's disease.
See More
